<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220409054465N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-04</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparision of the effect of Subdiaphragmatic Saline and sodium- bicharbonate Irrigation for Reducing Postoperative Shoulder Pain after Laparoscopic hysterctomy Surgeries</public_title>
      <acronym></acronym>
      <scientific_title>Comparision of the effect of Subdiaphragmatic Saline and sodium- bicharbonate Irrigation for Reducing Postoperative Shoulder Pain after Laparoscopic hysterctomy Surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-02-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73480</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: All patients undergo laparoscopic hysterectomy by a team of surgeons. And the intervention will be done based on the block randomization list by the operating room technician, and after random assignment, the patients will be divided into 3 groups. Randomization in this study is done in the form of block randomization. Randomly permuted blocks (block size of 3) will be generated using the website www.sealedenvelope.com and will be written on the drug envelopes.
After receiving the consent form and after confirming the eligibility of the patient, the random code will be randomized based on the randomization sheet by the main researcher and based on a predetermined randomization plan in the ratio of 1:1:1 to receive drug or serum or control. and receive their corresponding intervention box. This number was considered as the participant's randomization code and will be identified with this number until the end of the study.
Randomization using closed envelopes based on the type of medicine is given to the operating room technician and then the patients are followed up, Blinding description: After obtaining informed consent from the patient to participate in the study, the patient will not know the type of intervention he received. In order to hide the random allocation process, the sequence of treatments will be written on the cards in order, then the cards will be placed in sealed envelopes. A 10-digit random code will be written on each envelope without any order or frame, which is the identification number of the relevant patient, and only one of the executive agents of the project, who will not be involved in the evaluation, analysis and interpretation of the results, will be aware of the relevant code.
When another doctor (clinical caregiver) declares the eligibility of a patient, the nurse provides the envelope to the doctor and the desired surgical intervention will be performed based on the type mentioned in the envelope. And the results of the study will be checked by a outcome assessor who is unaware of the type of intervention. Due to the anesthesia during the surgery, the patients will not know the type of intervention. The statistics analyzer and the researcher will not be aware of the type of medicine used.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Reduction of shoulder pain after laparoscopic surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: In the first group (saline group): during normal surgery, 500 cc of saline is sprayed under the right hemodiaphragm before removing carbon dioxide. Intervention 2: Intervention group2:  In the second group (sodium bicarbonate group), 50 cc of 7.9% sodium bicarbonate (factory and country of manufacture) in 500 cc of 0.9% normal saline will be sprayed at the end of the surgery in the same way as the saline group. Intervention 3: In the control group (group 3), no intervention will be performed. At the end of the procedure, the patient is supine and the gas is released slowly.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Its release schedule is not yet known</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Lida Garrosi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehranpars street , Baghdarnia ave, Arash hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1653915981</zip>
        <telephone>9922 7771 21 98+</telephone>
        <email>Lgarrosi@zums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Lida garrosi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehranpars, Rashid BLV, Arash Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1653915981</zip>
        <telephone>9922 7771 21 98+</telephone>
        <email>lgarrosi@zums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Elective laparoscopic hysterectomy surgery
Age 20 to 60 years
ASA (anesthesia class) 1 and 2
No allergy to sodium bicarbonate
Absence of liver and kidney dysfunction
Absence of heart disease
Absence of previous shoulder pain or myofascial pain
Absence of cognitive impairment</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Unwillingness to participate in the study
Cancer of the uterus and ovaries
With severe intra-abdominal adhesions
History of underlying diseases (stroke, cerebral thrombosis, chronic hypertension, liver and kidney diseases)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: In the first group (saline group): during normal surgery, 500 cc of saline is sprayed under the right hemodiaphragm before removing carbon dioxide.</i_keyword>
      <i_keyword>Intervention group2:  In the second group (sodium bicarbonate group), 50 cc of 7.9% sodium bicarbonate (factory and country of manufacture) in 500 cc of 0.9% normal saline will be sprayed at the end of the surgery in the same way as the saline group</i_keyword>
      <i_keyword>In the control group (group 3), no intervention will be performed. At the end of the procedure, the patient is supine and the gas is released slowly.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Shoulder pain. Timepoint: 12,24,48 hours after surgery. Method of measurement: VAS questionnaire.</prim_outcome>
      <prim_outcome>Extra sedative. Timepoint: 12,24,48 hours after surgery. Method of measurement: number of requested sedative.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-30</approval_date>
        <contact_name>Tehran university of Medical science</contact_name>
        <contact_address>Qods street, Keshavarz boulevard Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
